2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.17

PP01.17 - Yuan Li

Pdf Summary

The study evaluates the cost-effectiveness of PD-L1 testing assays (VENTANA PD-L1 (SP263) Assay, Dako PD-L1 IHC 22C3 assay, and Dako 22C3 antibody concentrate) to guide immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) in China. Lung cancer, primarily NSCLC, is a significant health burden in China, with advanced stages commonly diagnosed. The National Health Commission recommends immunotherapy for patients with high PD-L1 expression, necessitating precise testing to determine eligibility.<br /><br />A decision tree model was developed from healthcare system perspectives and expert interviews to simulate costs and effectiveness of each assay. The VENTANA PD-L1 (SP263) Assay was found to be cost-effective, providing higher quality-adjusted life-years (QALYs) and lower total costs compared to the 22C3 alternatives. The study's time horizon was set to one year to adequately capture the costs and effectiveness of treatment approaches, aligning with the short treatment durations and survival times typical for advanced NSCLC patients.<br /><br />Sensitivity analyses confirmed the robustness of the results, showing that the SP263 assay has higher sensitivity and specificity, making it more suited for accurate diagnoses and appropriate treatment allocation. The SP263’s eligibility for multiple immune monotherapy regimens, including both Pembrolizumab and Atezolizumab monotherapies, contributes to its lower costs due to diverse medication choices.<br /><br />This study underscores the economic viability of the SP263 assay over its competitors, presenting a scientific foundation for selecting cost-effective diagnostics in precision medicine for NSCLC in China. Despite some limitations in data availability and assumed efficacy for false positives, the SP263 assay remains a superior economic option, aiming to enhance treatment accuracy and outcomes.

Keywords

PD-L1 testing assays

cost-effectiveness

NSCLC

VENTANA PD-L1 (SP263) Assay

immunotherapy

China

decision tree model

quality-adjusted life-years

sensitivity analyses

precision medicine